Sodium Phosphate P 32
Sodium phosphate P-32 is a radiopharmaceutical containing the beta-emitting radionuclide phosphorus-32, used for the palliative treatment of polycythemia vera, essential thrombocythemia, and bone metastases from hematologic malignancies. Phosphorus-32 is incorporated into rapidly proliferating cells, where its beta emissions deliver localized cytotoxic radiation to suppress abnormal hematopoiesis and reduce blood cell overproduction. It has a physical half-life of approximately 14.3 days.
分子量
142.9590 g/mol
TPSA
83.40 Ų
作用机制
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
二维结构
Cite this structure
Embed this structure
SMILES
O=[32P]([O-])([O-])O.[Na+].[Na+]
InChI
InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2/i;;5+1
Molecular Formula
HNa2O4P
HBD / HBA
1 / 4
可旋转键数
0
重原子数
7
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Sodium phosphate P-32 is a radiopharmaceutical containing the beta-emitting radionuclide phosphorus-32, used for the palliative treatment of polycythemia vera, essential thrombocythemia, and bone metastases from hematologic malignancies. Phosphorus-32 is incorporated into rapidly proliferating cells, where its beta emissions deliver localized cytotoxic radiation to suppress abnormal hematopoiesis and reduce blood cell overproduction. It has a physical half-life of approximately 14.3 days.
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
Yes, Sodium Phosphate P 32 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107525. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71180. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sodium-phosphate-p-32"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sodium-phosphate-p-32/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sodium-phosphate-p-32/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sodium-phosphate-p-32/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sodium-phosphate-p-32"></drugfyi-drug>